The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Methemoglobinemia

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about Methemoglobinemia.
Olatoyosi Odenike
Connection Strength
0.078
Methemoglobinemia
  1. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
    View in: PubMed
    Score: 0.078
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.